You are here

TTR-mediated amyloidosis

Alnylam Reports Positive Phase II Data for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR), and Initiates Phase III Trial

Yahoo/BusinessWire

Sun, 11/10/13 - 01:08 pm

TTR-mediated amyloidosis

Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)

Yahoo/BusinessWire

Sun, 06/30/13 - 10:42 am

TTR-mediated amyloidosis

Isis Pharmaceuticals Launches Trial, Hits Milestone

Motley Fool

Fri, 02/22/13 - 10:39 am

Isis Pharmaceuticals

transthyretin amyloidosis

TTR-mediated amyloidosis

Alnylam soars 31% on drug study

Marketwatch

Mon, 07/16/12 - 12:21 pm

TTR-mediated amyloidosis